Geneos Wealth Management
IMVT icon

Geneos Wealth Management’s Immunovant IMVT Stock Holding History

Geneos Wealth Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$33.8K Hold
1,000
– – ﹤0.01% 1875
2026
Q2 		$38.5K Hold
1,000
– – ﹤0.01% 1563
2026
Q1 		$24.8K Hold
1,000
– – ﹤0.01% 1694
2025
Q4 		$25.4K Buy
+1,000
New +$22.3K ﹤0.01% 1647

Other funds holding IMVT

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Geneos Wealth Management's IMVT Position: Q3 2026 in Review

Geneos Wealth Management held its Immunovant (IMVT) position steady in Q3 2026 at 1,000 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1875.

Geneos Wealth Management first reported a position in IMVT in Q4 2025 and has held it in 4 quarters since. The position peaked at $38.5K in Q2 2026. 81 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • Geneos Wealth Management held 1,000 shares of Immunovant worth $33.8K as of Q3 2026.
  • Geneos Wealth Management left its Immunovant share count unchanged in Q3 2026.
  • Immunovant made up ﹤0.01% of Geneos Wealth Management's portfolio in Q3 2026, its #1875 holding.
  • Geneos Wealth Management first reported a position in Immunovant in Q4 2025 and has held it in 4 quarters since.
  • Geneos Wealth Management's Immunovant position peaked at $38.5K in Q2 2026.
  • 81 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Geneos Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.